drugset / Trial / NCT00803283

A Study to Compare Safety and Efficacy of Osmotic Release Oral Syytem (OROS) Hydromorphone Hydrochloride (HCl) With Morphine Sustain Release (SR) in Participants With Cancer Pain

NCT00803283

Phase 3 Terminated 2 enrolled Johnson & Johnson Taiwan Ltd
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the effectiveness and safety of Osmotic Release Oral System (OROS) hydromorohone Hydrochloride (HCl) compared with morphine sustain release (SR) in participants with chronic (lasting a long time) malignant (cancerous) cancer pain.

Timeline

Start
2008-11
Primary completion
2008-12
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydromorphone Other / unclassified 8 mg
Comparator Morphine Other / unclassified 8 mg

Indications

No indication recorded.